{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:50:30Z","timestamp":1789905030070,"version":"4.0.1"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0184654","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T13:31:59Z","timestamp":1507210319000},"page":"e0184654","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-life results of sofosbuvir based therapy in chronic hepatitis C -na\u00efve and -experienced patients in Egypt"],"prefix":"10.1371","volume":"12","author":[{"given":"Ahmed","family":"Nagaty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4220-5859","authenticated-orcid":true,"given":"Ekram W.","family":"Abd El-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"EJ Gane","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJMc1307641","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"369","author":"E Lawitz","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"ref3","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.dld.2014.09.026","article-title":"Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies","volume":"46","author":"A Mangia","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"4","key":"ref4","first-page":"331","article-title":"Sofosbuvir: a novel oral agent for chronic hepatitis C","volume":"27","author":"E Cholongitas","year":"2014","journal-title":"Ann Gastroenterol"},{"key":"ref5","unstructured":"El-Zanaty F, Way A. Egypt health issue survey 2015. Cairo: Egyptian Ministry of Health and Population; El-Zanaty and Associates and Macro International. 2015."},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1086\/315786","article-title":"Genetic epidemiology of hepatitis C virus throughout egypt","volume":"182","author":"SC Ray","year":"2000","journal-title":"J Infect Dis"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2010.11.016","article-title":"Management of hepatitis C virus genotype 4: recommendations of an international expert panel","volume":"54","author":"MA Khattab","year":"2011","journal-title":"J Hepatol"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2893.2011.01576.x","article-title":"HCV burden of infection in Egypt: results from a nationwide survey","volume":"19","author":"J Guerra","year":"2012","journal-title":"J Viral Hepat"},{"issue":"1 Suppl","key":"ref9","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"E Gower","year":"2014","journal-title":"J Hepatol"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jvh.12668","article-title":"National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care","volume":"24","author":"W El-Akel","year":"2017","journal-title":"J Viral Hepat"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11901-012-0146-2","article-title":"Treatment of chronic HCV genotype 4 infection","author":"G Esmat","year":"2012","journal-title":"Curr Hepat Rep"},{"issue":"29","key":"ref12","first-page":"545","article-title":"Progress toward prevention and control of hepatitis C virus infection\u2014Egypt, 2001\u20132012","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"e10069","DOI":"10.5812\/hepatmon.10069","article-title":"The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study","volume":"13","author":"M El Raziky","year":"2013","journal-title":"Hepat Mon"},{"issue":"11","key":"ref14","first-page":"1510","article-title":"Factors Associated with Hepatitis C Infection among Chronic HCV Egyptian Patients","volume":"43","author":"EW Abd El-Wahab","year":"2014","journal-title":"Iran J Public Health"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/liv.12617","article-title":"A comprehensive hepatitis C virus risk factors meta-analysis (1989\u20132013): do they differ in Egypt?","volume":"35","author":"EM El-Ghitany","year":"2015","journal-title":"Liver Int"},{"issue":"28","key":"ref16","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.4254\/wjh.v7.i28.2792","article-title":"Hepatitis C genotype 4: The past, present, and future","volume":"7","author":"TY Abdel-Ghaffar","year":"2015","journal-title":"World J Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IJGM.S119301","article-title":"Hepatitis C in Egypt\u2014past, present, and future","volume":"10","author":"A Elgharably","year":"2017","journal-title":"Int J Gen Med"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2011.05.032","article-title":"Gaps in the achievement of effectiveness of HCV treatment in national VA practice","volume":"56","author":"JR Kramer","year":"2012","journal-title":"J Hepatol"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.21334","article-title":"FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients","volume":"44","author":"A Vallet-Pichard","year":"2006","journal-title":"Hepatology"},{"issue":"9883","key":"ref22","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"KV Kowdley","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/apt.12601","article-title":"Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection","volume":"39","author":"RS Koff","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","article-title":"Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4","volume":"63","author":"W Doss","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.10.044","article-title":"Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry","volume":"62","author":"PJ Ruane","year":"2015","journal-title":"J Hepatol"},{"issue":"S236","key":"ref26","article-title":"Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-na\u20ac\u0131ve patients with HCV infection: the QUANTUM study","volume":"58","author":"JP Lalezari","year":"2013","journal-title":"J Hepatol Int"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/apt.13923","article-title":"Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt","volume":"45","author":"A Elsharkawy","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 1","key":"ref28","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.1016\/S0168-8278(14)61272-1","article-title":"Long-term follow-up of patients treated with sofosbuvir in the Phase 3 studies FISSION, POSITRON, FUSION, and NEUTRINO","volume":"50","author":"W Cheng","year":"2014","journal-title":"Journal of Hepatology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12876-015-0328-9","article-title":"Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center &quot;real-life&quot; cohort","volume":"15","author":"N Steinebrunner","year":"2015","journal-title":"BMC Gastroenterol"},{"issue":"18","key":"ref30","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3748\/wjg.v19.i18.2793","article-title":"Sustained virological response: a milestone in the treatment of chronic hepatitis C","volume":"19","author":"F Morisco","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"20","key":"ref31","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"IM Jacobson","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","article-title":"Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"135","author":"S Maylin","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients","volume":"49","author":"SL George","year":"2009","journal-title":"Hepatology"},{"issue":"7","key":"ref34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more","volume":"52","author":"BL Pearlman","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.01.002","article-title":"Hepatitis C \u201ctrue\u201d late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy","volume":"66","author":"T Klag","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cid\/ciw676","article-title":"Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies","volume":"64","author":"C Sarrazin","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis","volume":"62","author":"B Simmons","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"13","key":"ref38","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"MW Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"SJ Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"ref40","article-title":"Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version","year":"2016"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with hepatitis C virus infection to boceprevir","volume":"143","author":"F Poordad","year":"2012","journal-title":"Gastroenterology"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/apt.13342","article-title":"Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naive patients with chronic HCV genotype 1 infection (ESSENTIAL II)","volume":"42","author":"S Zeuzem","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"20","key":"ref43","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"85","key":"ref44","first-page":"1407","article-title":"Splenectomy improves liver function in patients with liver cirrhosis","volume":"55","author":"K Murata","year":"2008","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1440-1746.2002.02667.x","article-title":"Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1","volume":"17","author":"T Akahoshi","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3892\/mmr.2013.1856","article-title":"The long-term effects of splenectomy and subsequent interferon therapy in patients with HCV-related liver cirrhosis","volume":"9","author":"Y Inagaki","year":"2014","journal-title":"Mol Med Rep"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bjid.2013.02.004","article-title":"Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis","volume":"17","author":"F Ji","year":"2013","journal-title":"Braz J Infect Dis"},{"issue":"5","key":"ref48","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1872-034X.2008.00481.x","article-title":"Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia","volume":"39","author":"D Morihara","year":"2009","journal-title":"Hepatol Res"},{"issue":"6","key":"ref49","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S1665-2681(19)31419-X","article-title":"Splenectomy in cirrhosis with hypersplenism: improvement in cytopenias, Child&apos;s status and institution of specific treatment for hepatitis C with success","volume":"11","author":"S Kedia","year":"2012","journal-title":"Ann Hepatol"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.transproceed.2013.12.034","article-title":"Clinical efficacy of simultaneous splenectomy in liver transplant recipients with hepatitis C virus","volume":"46","author":"H Morimoto","year":"2014","journal-title":"Transplant Proc"},{"issue":"41","key":"ref51","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.3748\/wjg.v20.i41.15387","article-title":"Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients","volume":"20","author":"B Feng","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12072-014-9586-9","article-title":"Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis","volume":"9","author":"H Tamai","year":"2015","journal-title":"Hepatol Int"},{"issue":"5","key":"ref53","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/jhep.2001.0103305le01","article-title":"Is splenectomy a cause of antiviral treatment failure in hepatitis C virus infection?","volume":"33","author":"R Parana","year":"2001","journal-title":"Hepatology"},{"issue":"7","key":"ref54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/apt.13095","article-title":"Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir","volume":"41","author":"RK Sterling","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"ref55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of Sofosbuvir, Ledipasvir\/Sofosbuvir, or Paritaprevir\/Ritonavir\/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System","volume":"151","author":"GN Ioannou","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"ref56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/liv.12722","article-title":"How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals","volume":"35","author":"L Serfaty","year":"2015","journal-title":"Liver Int"},{"issue":"1","key":"ref57","first-page":"172","article-title":"Interferon therapy in patients with chronic hepatitis C and schistosomiasis","volume":"32","author":"SM Kamal","year":"2000","journal-title":"J Hepatol"},{"issue":"5","key":"ref58","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"E Lawitz","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ref59","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jmv.24092","article-title":"Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients","volume":"87","author":"EW Abd El-Wahab","year":"2015","journal-title":"J Med Virol"},{"issue":"9","key":"ref60","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3748\/wjg.v23.i9.1697","article-title":"Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review","volume":"23","author":"AC Desbois","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"3","key":"ref61","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1478-3231.2009.02171.x","article-title":"Pioglitazone improves virological response to peginterferon alpha-2b\/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance","volume":"30","author":"M Khattab","year":"2010","journal-title":"Liver Int"},{"issue":"5","key":"ref62","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/apt.13300","article-title":"Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans","volume":"42","author":"LI Backus","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref63","article-title":"Treatment Adherence and Virologic Response Rates in HCV Infected Persons Treated with Sofosbuvir-based Regimens: Results from ERCHIVES","author":"AA Butt","year":"2016","journal-title":"Liver Int"},{"issue":"44","key":"ref64","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.3748\/wjg.v12.i44.7075","article-title":"Insulin resistance and hepatitis C","volume":"12","author":"M Romero-Gomez","year":"2006","journal-title":"World J Gastroenterol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0184654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T04:54:16Z","timestamp":1570164856000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0184654"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0184654","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}